Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate

Pharmacogenomics Journal

Volumn 8, Issue 2, 2008, Pages 147-151

  Karypidis, A H ^a   Olsson, M ^b   Andersson, S O ^c   Rane, A ^a   Ekstrom L ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B17; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; SWEDEN;

AGED; ANDROGENS; CASE-CONTROL STUDIES; GENE DELETION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GLUCURONOSYLTRANSFERASE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMERASE CHAIN REACTION; PROSTATE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; SWEDEN; UP-REGULATION;

EID: 40949134240     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500449     Document Type: Article

References (24)

1. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Canter Inst 1995; 87: 652-661.
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26
3. Lipsett MB. Estrogen use and cancer risk. J Am Med Assoc 1977; 237: 1112-1115.
4. Denis L, Mahler C. Prostatic cancer. An overview. Acta Oncol 1990; 29: 665-677.
5. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-224.
6. Imamov O, Lopatkin NA, Gustafsson JA. Estrogen receptor beta in prostate cancer. N Engl J Med 2004; 351: 2773-2774.
7. Hsing AW. Hormones and prostate cancer: What's next? Epidemiol Rev 2001; 23: 42-58.
8. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC et al 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992; 339: 887-889.
9. Lookingbill DP, Demers LM, Wang C, Leung A, Rittmaster RS, Santen RJ. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects, J Clin Endocrinol Metab 1991; 72: 1242-1248.
10. Hum DW, Belanger A, Levesque E, Barbier O, Beaulieu M, Albert C et al Characterization of UDP-glucuronosyltransferases active on steroid hormones. J Steroid Biochem Mol Biol 1999; 69: 413-423.
11. Barbler O, Lapointe H, El Alfy M, Hum DW, Belanger A. Cellular localization of uridine diphosphoglucuronosyltransferase 2B enzymes in the human. prostate by in situ hybridization and immunohistochemistry. J Clin Endocrinol Metab 2000; 85: 4819-4826.
12. Turgeon D, Carrier IS, Levesque E, Hum DW, Belanger A. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 2001; 142: 778-787.
13. Wilson III W, Pardo-Manuel de Villena F, Lyn-Cook BD, Chatterjee PK, Bell TA, Detwiler DA et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 2004; 84: 707-714.
14. Murata M, Warren EH, Riddell SR. A human minor histocompatibility, antigen resulting from differential expression due to a gene deletion. J Exp Med 2003; 197: 1279-1289.
15. Jakobsson J, Ekstrom L, Inotsume N, Gade M, Lorentzon M, Ohlsson C et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab 2006; 91: 687-693.
16. Park J, Chen L, Ratnashinge L, Sellers TA, Tanner JP, Lee JH et al Deletion polymorphism of UDP-glucuronosyltransferase 2817 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev 2006; 15: 1473-1478.
17. Levesque E, Beaulieu M, Green MD, Tephly TR, Belanger A, Hum DW. Isolation and characterization of UGT2B15(Y85): A UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 1997, 7: 317-325.
18. MacLeod SL, Nowell S, Plaxco J, Lang NP. An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer. Ann Surg Oncol 2000; 7: 777-782.
19. Park J, Chen I, Shade K, Lazarus P, Seigne J, Patterson S et al. Asp85tyr polymorphism in the UDP-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. J Urol 2004; 171: 2484-2488.
20. Guillemette C, Levesque E, Beaulieu M, Turgeon D, Hum DW, Belanger A. Differential regulation of two uridine diphospho-glucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells. Endocrinology 1997; 138: 2998-3005.
21. Soderstrom T, Wadelius M, Andersson SO, Johansson JE, Johansson S, Granath F et al. 5AIpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 2002; 12, 307-312.
22. Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999; 9 635-639.
23. Wadelius M, Autrup JL, Stubbins MI, Andersson SO, Johansson JE, Wadelius C et al. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics 1999; 9: 333-340.
24. Livak KI, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.